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ABSTRACT 
Objective: To describe the outcome of acute myeloid leukemia (AML) among children treat-
ed in Brazilian institutions. Methods: A structured online questionnaire was sent to pediatric 
oncologists affiliated to the Brazilian Society of Pediatric Oncology. The physicians and insti-
tutions were unidentified. Results: One hundred and four pediatric oncologists in all Brazilian 
regions answered the questionnaire. The treatment-related mortality rate was reported to 
be higher than 30% by 29.8% of the participants. Difficulty in accessing the intensive care 
unit (ICU) was reported by 54.8%. About 85% had access to cytogenetics, 78% to molecular 
testing, 94% to the measurement of residual disease by flow cytometry. About 90% of par-
ticipants reported access to HSCT, but 86% of them had difficulties in providing HSCT timely. 
About 95% of the participants indicated the need to create a national treatment protocol, 
and 89.4% are willing to collaborate with a national study group. Conclusion: Our study 
demonstrated large gaps in the treatment of pediatric AML. To improve outcome, a national 
protocol will have to consider the regional differences and adapt the management accord-
ing to the local resources. 
Keywords: Pediatric AML. HSCT. Brazil 
INTRODUCTION
Myeloid neoplasms represent a heterogeneous 
group of hematological disorders that originate 
from the myeloid, monocytic, erythroid and mega-
karyocytic precursors. Among them, acute myeloid 
leukemia (AML) is the most frequent in pediatric and 
adolescent age group, representing between 15-
20% of all acute leukemias 1. When treated with con-
ventional chemotherapy regimens, about 80-90% of 
these patients attain complete remission (CR). The 
5-year event-free survival (DFS) and overall survival 
(OS) rates approach 60% and 70%, respectively, in 
high-income countries [2, 3]. 
Eradication of the leukemia cells and restoration of 
the bone marrow function are the main treatment 
goals in AML. The use of intensive chemothera-
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py regimens to obtain rapid myelosupression is 
standard practice.  The combination of cytarabine, 
daunorubicin and etoposide form the basis of most 
remission induction treatment protocols [4, 6]. With 
two courses of intensive chemotherapy, the com-
plete remission (CR) rates are above 90%. Refractory 
or resistant disease rates are approximately 5% [2, 7]. 
Other strategies aimed to optimize the treatment in-
clude reducing the interval between the initial cycles 
of chemotherapy (“intensive timing”) 8 and replac-
ing daunorubicin with idarubicin 4 or mitoxantrone 
6. Several international study groups (BFM, CCG, NO-
PHO, LAME, MRC) have observed that the intensifica-
tion of induction along with optimal supportive care 
increases the CR but not the EFS rates [5, 9].
Post-remission strategies also did not improve EFS, 
because of failure to significantly reduce the relapse. 
The improvement of OS rates observed over the past 
25 years is due to improvements in salvage thera-
pies, including hematopoietic stem cell transplan-
tation (HSCT). The better outcome of pediatric AML 
after 1999 coincided with the broader utilization of 
HSCT. Without HSCT, the EFS and likely OS will not 
surpass 50%, irrespective of the frontline chemo-
therapy employed [10].
The intensity of the treatment utilized to attain and 
maintain remission, including HSCT in first or subse-
quent remission have raised concerns about acute 
and long-term side effects.  It is estimated that over 
30-40% of children with AML die from refractory dis-
ease/relapse or treatment-related toxicity 11. Recent 
studies have shown that the use of low-intensity in-
duction schemes can result in long-term remissions 
with less treatment-related toxicity, but with relaps-
es associated with the selection of treatment-resis-
tant clones [12, 13].
Central nervous system (CNS) therapy is a critical 
component in many therapeutic protocols because 
CNS relapse is relatively common in pediatric AML 
14. Intrathecal chemotherapy without cranial radio-
therapy has been used 5-7. Systemic minimal-mye-
lossuppressive maintenance therapy was routinely 
used in several protocols but because of the lack of 
benefits, most modern treatment protocols do not 
prescribe maintenance regimens [7, 11]. 
High rates of toxicity and death have been observed 
in the induction of AML in Brazil with the use of con-
ventional international protocols. Strategies to reduce 
the intensity of the regimens used in induction to de-
crease early treatment-related mortality might be an 
option for countries with limited resources. A study 
group,  within the Brazilian Society of Pediatric Oncol-
ogy (SOBOPE), denominated Childhood Acute Myeloid 
Leukemia Study Group (GELMAI), aims to start a dialog 
among pediatric oncologists of Brazilian institutions 
treating children and adolescents with AML and elab-
orate a uniform treatment protocol adapted to the lo-
cal resources. The strategy is to administer a minimally 
myelosuppressive regimen for the first induction re-
mission and risk-adapted therapy for the subsequent 
courses. The main goal is to avoid early treatment-re-
lated mortality. To initiate this effort, we developed a 
questionnaire directed to pediatric oncologists treat-
ing children and adolescents in institutions in different 
Brazilian regions.  In this study, we report an analysis of 
surveyed data provided by treating physicians on pedi-
atric AML in Brazil. 
METHODS
Study design
This is a transversal quantitative and descriptive 
study conducted in Brazil between 1st and 30th of 
May 2020 with pediatric oncologists associated with 
SOBOPE (Brazilian Society of Pediatric Oncology), 
based on the individual perception of the partici-
pants, without identifying the respective institutions. 
A multiple-choice online questionnaire developed 
by the GELMAI group containing 21 questions was 
sent by the google forms application to all pediatric 
oncologists registered with SOBOPE.
Variables included
The variables analysed included information re-
garding the number of medical doctors and multi-
disciplinary staff in each team, the number of avail-
able beds, the accessibility to exams, the treatment 
availability including chemotherapy, antibiotics, 
antifungals, transplantation of hematopoietic stem 
cells (HSCT), the access to intensive care and other 
items related to therapy and patient support. Using 
a dichotomous question, the interest of the medical 
doctors in participating in the protocol and national 
study group was consulted. 
Statistical analysis 
All answers were tabulated in excel format. Descrip-
tive statistical analyzes were used to calculate the 
absolute and relative values of each variable and 
graphic analyzes were included. All analysis were 
performed using Microsoft Excel 2016. 
Ethical approval 
This study was previously approved by the Ethics 
Committee (code CAAE: 53705016.7.1001.0097) and 
the ethical principles were in accordance with Decla-
ration of Helsinki on human subject research.
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RESULTS
The Brazilian Society of Pediatric Oncology (SOBOPE) 
have 272 registered medical doctors who received the 
questionnaire. From this cohort, 104 (38.2%) agreed to 
participate in this research. All regions of Brazil were 
represented, and the majority of participants (37.5%) 
were from the southeast region (figure 1). 
When questioned about AML pediatric treatment 
in Brazil, 97 (93.3%) believe that there is a need for a 
Brazilian treatment protocol for pediatric AML, and 
93 (89.4%) expressed interest in participating in the 
construction/elaboration of new protocols with 
SOBOPE. The quantification of all answers related 
to opinions regarding the institution is described 
in table 1. Institutions conditions are concerned 
especially related to the absence of HEPA filter in 
46 (44.2) cases and the impairment of care by the 
lack of a multi-professional team in 15 (14.4%) and 
lack of nursing staff in 18 (17.3%) of participating 
institutions. 
Table 2 describes the quantification of answers about 
treatment access and quality in pediatric AML care. 
Service quality is concerned in some of the aspects 
of patient treatment and care, especially regarding 
lack of access to blood transfusion for 14 (13.5%) of 
the participants, delay or absence of blood products 
during critical periods like holidays in 35 (33.6%) of 
the cases, rare access to prophylactic antifungals in 
15 (14.4%) of the cases and absence of HSCT for 7 
(6.7%) of the participating institutions.   
Figure 2 represents the exams access for AML diag-
nosis and disease control and management during 
treatment regardless of whether they are performed 
in the service or not (considering access of exams 
and results in a timely manner as not to compromise 
patient’s treatment). Despite being a developing 
country, almost half of the participants (47.1%) have 
access to the necessary exams for appropriated dis-
ease management. 
Figure 3 depicts the drugs available in the surveyed 
institutions. Among prophylactic antifungals, the 
most frequent used was micafungin. The chemo-
therapic agents most frequently used was idarubicin 
and between other classes such as cardioprotector 
was the cardioxane. 
Regarding the estimatives of number of AML pedi-
atric patients per year, mortality rate and the treat-
ment expectations (Table 3), it’s possible to observe 
that most participants manifested interest in partic-
ipating in a cooperative protocol. Furthermore, the 
estimated number of patients was less than five in 
42 (40.4%) of participating institutions and between 
6-10 n 39 (37.5%). Finally, the estimated mortality 
rate due to treatment complications was between 
11-30% in 43 (41.3%) of the participating institutions. 
DISCUSSION
Brazil is a developing country with about 209 million 
inhabitants; 56,4% of them residing in the southeast 
and south, the richest regions of the country. The 
median family income in Brazil is only up to US$ 330 
per month, depending on the region of the country 
15. Only 30% of the population have private med-
ical insurance 16 while the remaining individuals 
depend on governmental resources and structure, 
and cannot pay for  medical care. There is substan-
tial inequality in Brazil and due to informal econom-
ic networks, it is hard to generalize information and 
generates precise outcome data in each area. 
Low-income countries such as Brazil will present 
limitations regarding treatment options and labo-
ratory tests for diagnosis and disease follow-up. For 
instance, Brazil’s public health system (SUS, created 
in 1988), which attends the majority of Brazilian pa-
tients, has a considerable difficulty in sponsoring ge-
netic AML characterization of the diagnosis. Due to 
the high costs, access to diagnostic tests is limited to 
conventional karyotype. A few centers have access 
to a basic panel of molecular tests [17, 18].  
The high treatment intensity can partially explain the 
low rates of long-term survival among pediatric AML 
in Brazil patients. A study group with participants 
of different regions utilizing a uniform treatment 
protocol with predetermined adaptations for each 
institution has the potential to improve the overall 
outcome.  Understanding the real situation of the 
treatment of pediatric AML in Brazil will make possi-
ble to unify treatment approaches creating chemo-
therapy and supportive care guidelines, and a forum 
for ongoing discussion would allow for improved 
outcome. Mortality rates during induction remission 
remain high in developing countries but can be re-
duced by improved supportive care and adapted ini-
tial chemotherapy. It is expected that by discussing 
the case in group and adapting uniform treatment 
in real time, the early mortality will decrease. A Bra-
zilian study, that involved 1472 children and adoles-
cents, treated for acute lymphoid leukemia, showed 
an increase in survival among those treated on pro-
tocols when compared with those not enrolled on 
protocols [19]. 
Another important point is linked to treatment-relat-
ed cardiotoxicity, which significantly influences over-
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all survival and event-free survival, as demonstrated 
by the Children’s Oncology Group in AAML0531 trial 
20. Events may be acute during treatment, or late. 
Cardioprotection measures to mitigate and prevent 
this expected and unwanted adverse effect, in a so-
cially and economically diverse country such as Bra-
zil, requires a broad strategy that includes a detailed 
initial assessment of cardiac function, combined 
with cardioprotective use and continuous cardiac 
monitoring during and after treatment, in a rational 
and cost-effective manner [21]. 
The benefit of allogeneic HSCT as post-remission 
consolidation treatment in pediatric AML is well-doc-
umented in specific risk groups [22]. Pediatric AML in 
first CR and favorable karyotype may not be bene-
fited from allogeneic HSCT. The indications of allo-
geneic HSCT in first remission must take into con-
sideration the benefit and toxicity for those patients 
with an indeterminate prognosis; the objective is to 
decrease the rate of toxic death by avoiding HSCT 
in this group because the morbidity and mortality 
related to the procedure. In cases of definitive poor 
prognosis, the intention is to perform the HSCT in 
first remission. Because of the lack of laboratory sup-
port and other limitations related to the availability 
of transplantation in our country, we may not have 
opportunity to increase the number of HSCT in CR1 
as recommended. In the meantime, patients who re-
lapse should be considered for HSCT [23]. 
Improvements in genetic molecular classification, ef-
forts aiming to improve salvage therapy and increas-
ing access to HSCT will provide a better outcome for 
all these patients.
CONCLUSION 
Our study reveals the challenges of managing pe-
diatric AML in a country with limited resources and 
wide regional economic and cultural disparity. The 
understanding of the needs of each of the regions 
can be addressed by the implementation of uniform 
guidelines adapted to the current resources of each 
of the regions. A study group networking collabora-
tively with pediatric oncologists and hematologists 
from the diverse regions may bring changes that im-
prove to outcome of Brazilian children with AML.  
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TABLE 1 – Quantification of pediatric oncologists opinions regarding institution infrastructure for pediatric AML care
Regarding the number of medical professionals directly involved in leukemia 
treatments, in your service you consider that: N (%)
The team is adequate for the number of patients 64 (61.5)
The number is reduced, impairing the quality of care (care for children, considering the 
number of visits) 6 (5.8)
The number is reduced, generating overwork, but without compromising the quality of care 34 (32.7)
Regarding the number of beds for patient care in your ward: N (%)
Care is compromised due to lack of beds in some periods 14 (13.5)
The number of beds is adequate for the demand 49 (38.5)
The number of beds is generally adequate for the demand with periods of higher 
occupation, without seriously compromising the assistance 41 (39.4)
The AML patient N (%)
Shared bed with HEPA filter 7 (6.7)
Shared bed without HEPA filter 39 (37.5)
It is in an isolated bed with HEPA filter 12 (11.5)
It is in an isolated bed without HEPA filter 46 (44.2)
Regarding access to the ICU N (%)
Eventually there is some difficulty of vacancies, but patients are able to be served more than 
90% of the time without clinical damage 46 (44.2)
There is difficulty in access with clinical impairment in up to 25% of the time 7 (6.7)
There is difficulty in access with clinical impairment in more than 50% of the times 2 (1.9)
There is difficulty in access with clinical impairment between 25% and 50% of the time 2 (1.9)
Whenever necessary, we have a place in the ICU 47 (45.2)
Regarding the nursing team N (%)
The nursing team is adequate at the Hospital 40 (38.5)
Eventually there is a lack of professionals, but without serious damage to assistance 44 (42.3)
The nursing staff is deficient in relation to the number of patients frequently, impairing care 18 (17.3)
I prefer not to comment 2 (1.9)
Multiprofessional Team (except nursing) N (%)
The multidisciplinary team is adequate at the Hospital 44 (42.3)
The team at the Hospital is not complete, but the support institution helps us, maintaining 
adequate care 24 (23.1)
Eventually there is a lack of professionals, but without serious damage to assistance 21 (20.2)
Professionals are often lacking, impairing care 15 (14.4)
Support house (suitable or not) N (%)
The house sometimes lacks beds 19 (18.3)
The house often lacks beds 5 (4.8)
The house has beds available with ease 66 (63.5)
We don’t have or have a lot of difficulty with support house beds 9 (8.6)
I prefer not to comment 5 (4.8)
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TABLE 2 - Quantification of answers about treatment access and quality in pediatric AML care in Brazil
Regarding venous access, you consider that in your service N (%)
Most or almost all patients who need catheter access are able to place it in a timely manner 73 (70.2)
Some patients are able to place the catheter at the correct time, but others cannot 26 (25.0)
My patients have difficulty placing a catheter 5 (4.8)
Regarding the procedures (collection of CSF / Intrathecal / Myelogram) N (%)
Most procedures are performed at the time and under the conditions that I consider appropriate 34 (32.7)
I can do them in the time and under the conditions I consider appropriate 70 (67.3)
Regarding blood transfusion N (%)
I do not have access to irradiated and leukocyte-depleted blood components if necessary 14 (13.5)
I prefer not to comment 1 (1.0)
I have access to irradiated and leukocyte-depleted blood components if necessary 61 (58.6)
I have partial access to irradiated and leukocyte-depleted blood components if necessary 28 (26.9)
Your blood bank or transfusion agency N (%)
Meets needs almost always with rare delays or missing components 64 (61.5)
Delays frequently or we lack blood components frequently up to 50% of the time 5 (4.8)
Has occasional delays or absences, particularly during critical periods such as extended holidays 35 (33.6)
Do you think you have access to the prophylactic antifungals that you would like to use to 
treat AML N (%)
Eventually, but the administration or Infection Control Service makes it difficult to use 8 (7.7)
I prefer not to comment 5 (4.8)
Rarely 15 (14.4)
Yes 45 (43.3)
Yes, but the Infection Control service or administration makes it difficult to use 31 (29.8)
Regarding Bone Marrow Transplantation N (%)
More than 50% of patients are affected by delays 4 (3.8)
We don’t have access 7 (6.7)
I prefer not to comment 4 (3.8)
We have access at the Hospital or partner hospital and the same is done with delays affecting 
between 25% and 50% of patients in the queue 11 (10.6)
We have access at the Hospital or partner hospital and the same is done with delays affecting at 
least 25% of patients in the queue 24 (23.1)
We have access at the Hospital or partner hospital and the same is done with small delays 40 (38.5)
We have access at the Hospital or partner hospital and the same is done without delays 14 (13.5)
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TABLE 3 – Estimatives and expectations of pediatric AML treatment protocol and outcomes for medical doc-
tors of Brazilian institutions. 
Regarding to the treatment of pediatric AML (except M3 and Down syndrome), you: N (%)
Would you be willing to participate in a cooperative protocol 73 (70.2)
Will continue the local protocol or already participate in another group 1 (1.0)
Participate depending on the type of protocol proposed 29 (27.9)
Prefer to have only a treatment guide made 1 (1.0)
What number of pediatric AML patients does the service serve per year? N (%)
16-20 7 (6.7)
More than 26 1 (1.0)
Less than 5 42 (40.4)
I don’t know 3 (2.9)
11-15 12 (11.5)
6-10 39 (37.5)






Above 51% 9 (8.6)
I don’t know 13 (12.5)
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GRAPHIC 1 – Institutions participating in the study according to the region of Brazil
GRAPHIC 2 – Number of Brazilian institutions that have access to the specialty tests regardless of whether 
they are performed locally.
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GRAPHIC 3 - Treatment availability in the Brazilian surveyed institutions.
